Search by Drug Name or NDC
NDC 00310-6524-01 Byetta 250 ug/mL Details
Byetta 250 ug/mL
Byetta is a SUBCUTANEOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AstraZeneca Pharmaceuticals LP. The primary component is EXENATIDE.
MedlinePlus Drug Summary
Exenatide is used along with diet and exercise to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) in adults (Byetta) and in adults and children 10 years of age and older (Bydureon BCISE). Exenatide is in a class of medications called incretin mimetics. It works by stimulating the pancreas to secrete insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. Exenatide also slows the emptying of the stomach and causes a decrease in appetite. Exenatide is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). Exenatide is not used instead of insulin to treat people with diabetes who need insulin. Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Using medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
Related Packages: 00310-6524-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Exenatide Injection
Product Information
NDC | 00310-6524 |
---|---|
Product ID | 0310-6524_7d116557-6fe2-4179-af97-7e2fc5935d38 |
Associated GPIs | 2717002000D240 |
GCN Sequence Number | 059073 |
GCN Sequence Number Description | exenatide PEN INJCTR 10MCG/0.04 SUBCUT |
HIC3 | C4I |
HIC3 Description | ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEP.AGONIST) |
GCN | 24614 |
HICL Sequence Number | 032893 |
HICL Sequence Number Description | EXENATIDE |
Brand/Generic | Brand |
Proprietary Name | Byetta |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | exenatide |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION |
Route | SUBCUTANEOUS |
Active Ingredient Strength | 250 |
Active Ingredient Units | ug/mL |
Substance Name | EXENATIDE |
Labeler Name | AstraZeneca Pharmaceuticals LP |
Pharmaceutical Class | GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA021773 |
Listing Certified Through | 2024-12-31 |
Package
NDC 00310-6524-01 (00310652401)
NDC Package Code | 0310-6524-01 |
---|---|
Billing NDC | 00310652401 |
Package | 1 CARTRIDGE in 1 CARTON (0310-6524-01) / 2.4 mL in 1 CARTRIDGE |
Marketing Start Date | 2014-12-12 |
NDC Exclude Flag | N |
Pricing Information | |
Price Per Unit | 340.859 |
Pricing Unit | ML |
Effective Date | 2024-01-01 |
NDC Description | BYETTA 10 MCG DOSE PEN INJ |
Pharmacy Type Indicator | C/I |
OTC | N |
Explanation Code | 4, 5 |
Classification for Rate Setting | B |
As of Date | 2024-02-21 |